2014
DOI: 10.1007/s40273-014-0231-1
|View full text |Cite
|
Sign up to set email alerts
|

A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis

Abstract: This review found a substantial number of published cost-effectiveness analyses of drugs in osteoporosis in the last 6 years. Results and critical appraisal of these articles can help decision makers when prioritizing health interventions and can inform the development of future economic evaluations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
65
0
1

Year Published

2015
2015
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 84 publications
(70 citation statements)
references
References 68 publications
4
65
0
1
Order By: Relevance
“…Our analysis also only considered the effect of a hip fracture service on the immediate perioperative period, and did not account for the future downstream benefit of increased initiation of osteoporosis treatment, which has been shown to be better in a comanagement model [22,28] and also to be net cost effective [31,32,35], but this is a much more remote benefit. Additionally, although a few studies have reported improved readmission rates with comanagement [5,39], others have reported no change [17,24,28,52].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Our analysis also only considered the effect of a hip fracture service on the immediate perioperative period, and did not account for the future downstream benefit of increased initiation of osteoporosis treatment, which has been shown to be better in a comanagement model [22,28] and also to be net cost effective [31,32,35], but this is a much more remote benefit. Additionally, although a few studies have reported improved readmission rates with comanagement [5,39], others have reported no change [17,24,28,52].…”
Section: Discussionmentioning
confidence: 99%
“…Highquality economic studies have evaluated the benefits of directing resources toward the focused goal of reducing time to the operating room [19] and the benefits of early initiation of osteoporosis treatment [31,32,35]. Additionally, numerous studies have identified important predictors of perioperative complications, costs, and mortality [5,13,18,41,46,49,53,54,65], suggesting that different patient populations may have different predisposing risk factors, and thus experience different degrees of benefit from a comanagement system.…”
Section: Introductionmentioning
confidence: 99%
“…Relative risk reductions of spine and non-vertebral fractures by TABM in subjects with bone densitometry diagnosed osteoporosis are 40-60% and 20-40%, respectively (14,61). Number-Needed-to-Treat (NNT) to prevent a fracture is lower in people at high risk of fractures, and especially in those with prior fragility fractures (13,37,(61)(62)(63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73).…”
Section: Primary and Secondary Prevention Related To Bone Healthmentioning
confidence: 99%
“…In the field of osteoporosis, the number of economic evaluations has increased markedly in recent years [3, 4]. Economic evaluations have been conducted to assess the cost-effectiveness of anti-osteoporotic drugs [3, 5, 6], to identify cost-effective intervention thresholds for fracture risk [79], and to estimate the cost-effectiveness of osteoporosis programs for screening patients [10, 11] or fracture liaison services for secondary fracture prevention [12].…”
Section: Introductionmentioning
confidence: 99%